Sanaria is a finalist in Vaccine Industry Excellence (VIE) awards for Best Logistics Technology & Cold Chain Delivery Award
To protect against and eliminate malaria, the world needs a vaccine that has >90% vaccine efficacy against infection with naturally transmitted Plasmodium falciparum (Pf) parasites. Pf is responsible for >98% of the annual 625,000 deaths from malaria.
Only Sanaria’s Pf sporozoite (PfSPZ) vaccines have achieved >90% VE against controlled human malaria infections and shown sustained protection without boosting against natural transmission in Africa. Sanaria’s PfSPZ vaccines are composed of PfSPZ harvested from the salivary glands of aseptically reared mosquitoes, that are then purified, vialed, and cryopreserved.
PfSPZ vaccines are live eukaryotic cell vaccines that are transported all over the world at temperatures below -150 °C using a robust liquid nitrogen vapor phase (LNVP) cold chain that can run independently of electricity, which can be unreliable or absent, or other energy sources (propane, kerosene). The cold chain allows mass storage to last mile delivery using LNVP cryoshippers which can hold vaccine for up to 28 days, ideal for the remote regions where malaria health facilities are often not available.
To ensure that PfSPZ vaccines can be used anywhere rather than in specialist facilities, Sanaria has developed a unique plastic cryovial with a septum that maintains closure integrity at ultra-low temperatures. These two innovations mean that vaccine can be delivered to any remote location for administration rather than recipients needing to travel to clinics for immunizations.
The PfSPZ vaccines cold chain covers all steps from fill-finish, through high stability storage, global distribution and last mile, ending at vaccine thawing and administration by syringe, and a cost-efficient, hub-and-spoke distribution system adaptable for use in all situations has been modeled suggesting that PfSPZ vaccines will be accessible, affordable and implementable. To date, PfSPZ vaccines have been successfully delivered, stored locally, and administered to volunteers in 38 clinical trials, including in 7 African countries and Indonesia, often in remote settings.
The 17th Annual ViE Awards 2024, part of the World Vaccine Congress Washington, will celebrate the industry’s most outstanding achievements. With 13 categories, these awards have been created to honor and generate recognition of the efforts, accomplishments, and positive contributions of companies and individuals in the vaccine industry. Sanaria is grateful for being recognized as one of six finalists in this year’s nominations for “Best Logistics Technology & Cold Chain Delivery Award.”
Other finalists include DHL, Siemens, UPS, Cerba Research, and World Courier.
